{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T04:52:10Z","timestamp":1778043130426,"version":"3.51.4"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,12,19]],"date-time":"2017-12-19T00:00:00Z","timestamp":1513641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","award":["CW214392"],"award-info":[{"award-number":["CW214392"]}],"id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EBioMedicine"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.ebiom.2017.12.024","type":"journal-article","created":{"date-parts":[[2017,12,20]],"date-time":"2017-12-20T14:17:34Z","timestamp":1513779454000},"page":"182-186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Testosterone Diminishes Cabazitaxel Efficacy and Intratumoral Accumulation in a Prostate Cancer Xenograft Model"],"prefix":"10.1016","volume":"27","author":[{"given":"Lisanne","family":"Mout","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"de Wit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debra","family":"Stuurman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Verhoef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron","family":"Mathijssen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corrina","family":"de Ridder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martijn","family":"Lolkema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wytske","family":"van Weerden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2017.12.024_bb0005","first-page":"5001-5001","article-title":"A randomized phase III trial between adjuvant docetaxel andsurveillance after radical prostatectomy for high risk prostate cancer: Results of SPCG12","volume":"34","author":"Ahlgren","year":"2016","journal-title":"ASCO J. Clin. Oncol."},{"key":"10.1016\/j.ebiom.2017.12.024_bb0010","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ebiom.2017.12.024_bb0015","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jpba.2011.10.010","article-title":"Quantification of cabazitaxel in human plasma by liquid chromatography\/triple-quadrupole mass spectrometry: a practical solution for non-specific binding","volume":"59","author":"de Bruijn","year":"2012","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ebiom.2017.12.024_bb0020","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/pcan.2016.42","article-title":"Role of OATP transporters in steroid uptake by prostate cancer cells in vivo","volume":"20","author":"Green","year":"2017","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.ebiom.2017.12.024_bb0025","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ebiom.2017.12.024_bb0030","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/ijc.21201","article-title":"Androgen receptor modifications in prostate cancer cells upon long-termandrogen ablation and antiandrogen treatment","volume":"117","author":"Marques","year":"2005","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ebiom.2017.12.024_bb0035","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.eururo.2005.12.035","article-title":"The human PC346 xenograft and cell line panel: a model system for prostate cancer progression","volume":"49","author":"Marques","year":"2006","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ebiom.2017.12.024_bb0040","doi-asserted-by":"crossref","first-page":"e13500","DOI":"10.1371\/journal.pone.0013500","article-title":"Bypass mechanisms of the androgen receptor pathway in therapy-resistant prostate cancer cell models","volume":"5","author":"Marques","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.ebiom.2017.12.024_bb0045","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1093\/annonc\/mds119","article-title":"Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?","volume":"23","author":"Mezynski","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ebiom.2017.12.024_bb0050","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/pros.23182","article-title":"Understanding taxanes in prostate cancer; importance of intratumoral drug accumulation","volume":"76","author":"de Morree","year":"2016","journal-title":"Prostate"},{"key":"10.1016\/j.ebiom.2017.12.024_bb0055","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/bjc.2016.251","article-title":"Loss of SLCO1B3 drives taxane resistance in prostate cancer","volume":"115","author":"de Morree","year":"2016","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ebiom.2017.12.024_bb0060","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1016\/j.ejca.2013.09.026","article-title":"Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer","volume":"49","author":"van Soest","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ebiom.2017.12.024_bb0065","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.eururo.2016.05.030","article-title":"Improving survival for metastatic castrate-resistant prostate cancer: will combination therapy help us to move forward?","volume":"70","author":"Sternberg","year":"2016","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ebiom.2017.12.024_bb0070","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N. Engl. J. Med."}],"container-title":["EBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396417305054?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396417305054?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T18:49:20Z","timestamp":1762454960000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396417305054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":14,"alternative-id":["S2352396417305054"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2017.12.024","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Testosterone Diminishes Cabazitaxel Efficacy and Intratumoral Accumulation in a Prostate Cancer Xenograft Model","name":"articletitle","label":"Article Title"},{"value":"EBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2017.12.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}